Gene therapy

#Biomarkers #Collaboration #Gene mutation #Gene therapy

Illumina and Merck partner to identify cancer mutations 

Illumina and Merck have partnered to develop and commercialise tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD).   Patients whose tumours are HRD-positive may be eligible for targeted treatment by a class of precision medicines called PARP inhibitors. The HRD tests will leverage Illumina’s TruSight Oncology 500 (TSO… Read More

#News

#Gene therapy #Technology

Partnership aims to improve gene therapy manufacturing 

Aptamer Group and Bio-Works Technologies have entered into an agreement to develop an affinity resin for improved purification and scale up of gene therapy vectors.  Under the agreement, Aptamer Group will develop an Optimer ligand capable of binding and eluting of a viral vector. Bio-Works Technologies will then develop a derivatised resin by coupling… Read More

#Business & Investment #News

#Biotherapeutics #Gene therapy #Global data

Gene therapies could revolutionise CVDs, data says 

Gene therapies could revolutionise the management of chronic cardiovascular diseases (CVDs) such as heart failure, according to GlobalData. The data and analytics company notes that there are currently 87* CVD gene therapies currently in development, and they hold potential to vastly improve patients’ quality of life.  Fiona Chisholm, Pharma Analyst at GlobalData said: “As… Read More

#Market Reports #News #Trends & Analysis

#Biomedicine #Digital focus #Gene therapy #Life sciences #MS #Narrated podcasts

Streamlining gene therapy and how MS provides information on virus structure

In this podcast, Megan Thomas narrated two articles in which Akash Bhattacharya, the Senior Application Scientist at Beckman Coulter Life Sciences, explains how streamlining gene therapy manufacturing will help products reach more patients, and Andreas Huhmer, Senior Director of Proteomics and Metabolomics at Thermo Fisher Scientific, discusses the value of… Read More

#Podcasts

#Clinical trials #Gene editing #Gene mutation #Gene therapy #Genetics / genomics #Research

Exploring gene-based medicine’s true potential

Listen to this article on the DDW Podcast: By Christopher Doyle, PhD, Director, IBC Services at WCG The Covid-19 pandemic spawned a flurry of research that culminated in the development of several vaccines that express viral proteins from recombinant or synthetic genetic material. The success of these new vaccines thrust the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Gene therapy #Neurodegenerative disorders #Research

Gene therapy enables new treatments for neurodegenerative diseases

The University of Sheffield and the Cell and Gene Therapy Catapult have launched a gene therapy programme which could pave the way for novel treatments for neurodegenerative diseases. The research has been awarded £513,141 from LifeArc and the Motor Neurone Disease Association to test the feasibility and efficiency of a… Read More

#News

#Cancer research #DNA #Gene sequencing #Gene therapy

New drug class can kill cancer cells with BRCA gene mutations

Scientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumours have faulty copies of the BRCA cancer genes. The drugs, known as POLQ inhibitors, specifically kill cancer cells with mutations in the BRCA genes while leaving healthy cells unharmed. Crucially, they… Read More

#News

#Drug development #Gene therapy #mRNA #Therapeutics

Evonik to develop new drug delivery platform for mRNA

Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). Starting in June 2021, Evonik and Stanford scientists begin a three-year sponsored research collaboration to develop the polymer-based drug delivery system, which Evonik will license… Read More

#News

Doctor administering a vaccine to patient
#Drug delivery #Drug development #Gene therapy #In vivo

Collaboration expands reach in next generation vaccines

Gamma Biosciences has agreed to make a controlling investment in Mirus Bio for nucleic acid delivery based in Madison, Wisconsin. The transaction will support Mirus’ plans to expand good manufacturing practice (GMP) production and commercialisation of its flagship product TransIT VirusGEN for large scale manufacturing of AAV and LV-based viral… Read More

#News

#Bioscience #Cell and gene therapy #Gene therapy

Cell & Gene Collective to advocate for adoption of next generation medicine

The Cell & Gene Collective has been launched by companies Astellas, bluebird bio, Bristol Myers Squibb, Kite (a Gilead company) and Novartis with the aim of raising awareness of the promise and challenges of the next generation of medicines – cell and gene therapies. To date, the UK has… Read More

#News

#Bioscience #Cell and gene therapy #DNA #Gene therapy

Charles River acquisition enhances gene therapy capabilities

Charles River has signed a definitive agreement to acquire Vigene Biosciences. The purchase price is expected to be US$292.5 million, subject to customary closing adjustments. The acquisition will enhance Charles River’s gene therapy capabilities in the high-growth, value-added cell and gene therapy CDMO sector. In addition to the initial purchase… Read More

#News

#Antibody #Clinical trials #Gene therapy #MND #Motor neurone disease #Therapeutics

Joint fund to accelerate search for motor neurone disease treatments

Medical research charity LifeArc and the MND Association have established a £1 million joint translational research fund to support researchers developing treatments for Motor Neurone Disease (MND). Despite recent advances, there is still no effective clinical treatment for MND. Each organisation is contributing £500,000 to the fund. Researchers from across… Read More

#News

#Corning Life Sciences #Drug delivery #Drug development #Drug discovery #Gene therapy #Genetics #Genetics / genomes #Life sciences #Research

Process Development in Gene Therapy: Four Things to Know

By John Yoshi Shyu, Ph.D. Corning Life Sciences. Gene therapy – the addition, deletion, or modification of genes in living organisms – has been around, at least in concept, since the 1980s. Gene modification or editing incorporates two main strategies: insertion of novel genetic constructs into existing genes, and gene… Read More

#Exclusive Content #News

#Clinical trial #Drug delivery #Drug development #Drug discovery #Gene therapy

Genethon doses first patient in clinical trial of gene therapy for DMD

The first dose of the investigational gene therapy GNT 0004 was given for Dunchenne Muscular Dystrophy (DMD) at I-Motion, the paediatric clinical trial platform for neuromuscular diseases in Paris. The young boy was the first patient in an international phase I/II/III multicentre trial, sponsored by Genethon. The trial has been… Read More

#News